All Releases
 |
ARYx Therapeutics Schedules First Quarter 2008 Results and Earnings Call and Clarifies Expiration of Lock-Up Period
Apr 30, 2008
|
12.3 KB |
|
| |
FREMONT, Calif., Apr 30, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today a conference call to discuss first quarter 2008 results will be held on Tuesday, May 13, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 866-356-4123
Dial In (I...
|
|
ARYx to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
Apr 25, 2008
|
10.5 KB |
|
| |
FREMONT, Calif., Apr 25, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, Florida. A live webcast of the presentation scheduled for Friday, May 2 at 9:10 a.m. Eastern Time may be accessed at the ARYx website http://ww...
|
|
ARYx Therapeutics Enters Clinic with Novel Antipsychotic Drug for Patients with Schizophrenia
Apr 22, 2008
|
13.4 KB |
|
| |
FREMONT, Calif., Apr 22, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has received clearance from the Food and Drug Administration (FDA) to initiate clinical testing of ATI-9242, a novel antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company has begun dosing healthy vol...
|
|
ARYx Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results
Mar 12, 2008
|
20.4 KB |
|
| |
FREMONT, Calif., Mar 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (Nasdaq:ARYX) today reported financial results for the fourth quarter and year ended December 31, 2007.
"2007 was a year of tremendous growth and accomplishment for ARYx," said Dr. Paul Goddard, chairman and chief executive officer of ARYx. "During this productive year, we...
|
|
ARYx Therapeutics Schedules Fourth Quarter and Year End 2007 Results and Earnings Call
Mar 6, 2008
|
9.9 KB |
|
| |
FREMONT, Calif., Mar 06, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ: ARYX), a biopharmaceutical company, announced today a conference call to discuss fourth quarter and year ended December 31, 2007 results on Wednesday, March 12, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In...
|
|
ARYx Therapeutics Provides Update on Product Development -- Reports Results for 2007 Third Quarter
Dec 20, 2007
|
22.4 KB |
|
| |
FREMONT, Calif., Dec 20, 2007 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, today provided an update on the development of their products and reported financial results for the three and nine months ended September 30, 2007.
Highlights for the Quarter
The highlights in the development of our products...
|
|
ARYx Therapeutics Schedules Third Quarter 2007 Results and Earnings Call
Dec 12, 2007
|
9.8 KB |
|
| |
FREMONT, Calif., Dec 12, 2007 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today a conference call to discuss third quarter results on Thursday, December 20, 2007, at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 800-884-5695
Dial In...
|
|
ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
Nov 7, 2007
|
9.3 KB |
|
| |
FREMONT, California, November 7, 2007 - ARYx Therapeutics, Inc. announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a price of $10.00 per share. All shares are being offered by ARYx Therapeutics. In addition, ARYx Therapeutics has granted the underwriters a 30-day option to purchase up to an add...
|
|
ARYx Therapeutics Files Registration Statement for Initial Public Offering
Aug 30, 2007
|
8.8 KB |
|
| |
August 30, 2007 - Fremont, CA
ARYx Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by ARYx Therapeutics.
The unde...
|
|
ARYx Therapeutics Appoints New Chief Development Officer
Feb 21, 2007
|
9.1 KB |
|
| |
February 21, 2007 - Fremont, CA
ARYx Therapeutics, a private drug discovery and development company, today announced that it has named Daniel M. Canafax, Pharm.D. as its new chief development officer. Dr. Canafax, a 30-year veteran in the field of clinical research and development, will be responsible for the continued advancement of ...
|
|
ARYx Therapeutics President & Co-Founder Elected to California Healthcare Institute Board
Nov 15, 2006
|
9.8 KB |
|
| |
November 15, 2006 - LA JOLLA, CALIF.
Peter G. Milner, M.D., F.A.C.C., president, co-founder and, member, board of directors, ARYx Therapeutics, Inc., was elected to the board of directors of California Healthcare Institute (CHI). CHI is a non-profit public policy research organization, representing leading California academic institut...
|
|
ARYx Therapeutics President & Co-Founder Elected to California Healthcare Institute Board
Nov 15, 2006
|
9.2 KB |
|
| |
November 15, 2006 - LA JOLLA, CALIF.
Peter G. Milner, M.D., F.A.C.C., president, co-founder and, member, board of directors, ARYx Therapeutics, Inc., was elected to the board of directors of California Healthcare Institute (CHI). CHI is a non-profit public policy research organization, representing leading California academic institution...
|
|
Procter & Gamble Pharmaceuticals and ARYx Therapeutics Form Alliance for an Investigational Treatment for Gastrointestinal Disorders
Jul 11, 2006
|
14.4 KB |
|
| |
July 11, 2006 - Cincinnati, Ohio, and Fremont, California
Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG) and ARYx Therapeutics, a private drug discovery and development company, today announced a strategic alliance under which P&G will develop and commercialize ARYx's novel drug, ATI-7505, ...
|
|
Procter & Gamble Pharmaceuticals and ARYx Therapeutics Form Alliance for an Investigational Treatment for Gastrointestinal Disorders
Jul 11, 2006
|
14.4 KB |
|
| |
July 11, 2006 - Cincinnati, Ohio, and Fremont, California
Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG) and ARYx Therapeutics, a private drug discovery and development company, today announced a strategic alliance under which P&G will develop and commercialize ARYx's novel drug, ATI-7505, f...
|
|
ARYx Therapeutics Appoints Herm Rosenman to Board of Directors
Feb 21, 2006
|
9.6 KB |
|
| |
February 21, 2006 - Fremont, CA
ARYx Therapeutics, a private drug discovery and development company, today announced the appointment of Herm Rosenman to its board of directors. Mr. Rosenman is a long-time executive with significant experience in financial operations, initial public offerings, and SEC reporting. He will chair ARYx's Au...
|
|
ARYx Therapeutics Appoints Herm Rosenman to Board of Directors
Feb 21, 2006
|
9.3 KB |
|
| |
February 21, 2006 - Fremont, CA
ARYx Therapeutics, a private drug discovery and development company, today announced the appointment of Herm Rosenman to its board of directors. Mr. Rosenman is a long-time executive with significant experience in financial operations, initial public offerings, and SEC reporting. He will chair ARYx's Audit...
|
|
ARYx Therapeutics Completes Series E Financing
Feb 7, 2006
|
10.3 KB |
|
| |
February 7, 2006 - Fremont, Calif.
ARYx Therapeutics Inc., a private drug discovery and development company, announced today that it has completed a $30.4 million Series E financing led by Ascent Biomedical Ventures. The company plans to use the funds to continue developing its three clinical programs, ATI-2042, ATI-7505 and ATI-5923 ...
|
|
ARYx Therapeutics Completes Series E Financing
Feb 7, 2006
|
9.6 KB |
|
| |
February 7, 2006 - Fremont, Calif.
ARYx Therapeutics Inc., a private drug discovery and development company, announced today that it has completed a $30.4 million Series E financing led by Ascent Biomedical Ventures. The company plans to use the funds to continue developing its three clinical programs, ATI-2042, ATI-7505 and ATI-5923 thr...
|
|
ARYx Therapeutics Appoints Former Amgen Exec to Board
Aug 18, 2005
|
9.6 KB |
|
| |
August 18, 2005 - Freemont, Calif.
ARYx Therapeutics today announced the appointment of Keith R. Leonard to its board of directors. Leonard is a 13-year veteran of Amgen Inc. and currently serves as president and CEO of AESTHERx Inc.
"We are delighted to add an executive of Mr. Leonard's caliber to our board," said Paul Goddar...
|
|
ARYx Therapeutics Appoints Former Amgen Exec to Board
Aug 18, 2005
|
9.3 KB |
|
| |
August 18, 2005 - Freemont, Calif.
ARYx Therapeutics today announced the appointment of Keith R. Leonard to its board of directors. Leonard is a 13-year veteran of Amgen Inc. and currently serves as president and CEO of AESTHERx Inc.
"We are delighted to add an executive of Mr. Leonard's caliber to our board," said Paul Goddard, ...
|
|
|
Print page 
Email page 
Shareholder Briefcase
Printed Materials
Download Library
Glossary
RSS News Feeds
